EQT, BCBP, FIX, PAAS and ADMA have been added to the Zacks Rank #1 (Strong Buy) List on March 25, 2026.
LCUT, EFXT, MGA, ADMA and JLL have been added to the Zacks Rank #1 (Strong Buy) List on March 23, 2026.
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $15.02, denoting a +1.01% move from the preceding trading day.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
B Group Inc. grew its stake in ADMA Biologics Inc (NASDAQ: ADMA) by 4.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,412,542 shares of the biotechnology company's stock after purchasing an additional 95,000 shares during the quarter. ADMA Biologics
Adma Biologics (ADMA) concluded the recent trading session at $15.15, signifying a +1.03% move from its prior day's close.
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position TERN, ADMA, ANIP and LQDA in this volatile sector.
Adma Biologics (ADMA) reached $14.99 at the closing of the latest trading day, reflecting a -4.34% change compared to its last close.
ADMA, RELY and HSY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 12th, 2026.
AEO, RELY, ADMA, HSY and HTBK have been added to the Zacks Rank #1 (Strong Buy) List on March 12th, 2026.
Adma Biologics (ADMA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?